Document is current
Any future updates will be listed below
-
Authors
Dayan, Davut http://orcid.org/0000-0003-1589-2016
Lukac, Stefan http://orcid.org/0000-0002-9336-2267
Rack, Brigitte
Ebner, Florian http://orcid.org/0000-0003-2066-5344
Fink, Visnja
Leinert, Elena http://orcid.org/0000-0001-5795-3417
Veselinovic, Kristina
Schütze, Sabine
El Taie, Ziad
Janni, Wolfgang
Friedl, Thomas W. P. http://orcid.org/0000-0002-4773-8067
-
Funding
Funding for this research was provided by:
Universität Ulm
- License Information
-
More Information
Article History
Received: 31 January 2023
Accepted: 4 December 2023
First Online: 14 December 2023
Declarations
:
: The Federal Institute for Drugs and Medical Devices (BfArM) and the relevant ethics committees approved the SUCCESS studies (Success A: Ludwig Maximilian University Munich, 076/05; Success B: Ludwig Maximilian University Munich, 395/07; Success C: Heinrich-Heine University Duesseldorf, MC-LKP-319), which were performed in accordance with Good Clinical Practice and the Declaration of Helsinki. Written informed consent was obtained from all patients.
: Thomas WP Friedl received honoraria from Novartis and Lilly unrelated to this work. Florian Ebner received honoraria from Gedeon Richter and Helios Forschungsförderung unrelated to this work. The other authors declare that they have no conflicts of interest.
